From Molecules to Medicine: New Horizons in Vascular Biology and Thrombosis

Thromb Haemost 2008; 99(02): 251-252
DOI: 10.1160/TH08-01-0026

Theme Issue Editorial

Schattauer GmbH

Klaus T. Preissner^*

¹Institute for Biochemistry, Medical School, Justus-Liebig-University, Giessen, Germany

References
1 Nurden P, Nurden AT. Congenital disorders associated with platelet dysfuntions. Thromb Haemost 2008; 99: 253-263.
2 Bergmeier W, Chauhan AK, Wagner DD. Glycoprotein Ibα and von Willebrand factor in primary platelet adhesion and thrombus formation: lessons from mutant mice. Thromb Haemost 2008; 99: 264-270.
3 Denis CV, Christophe OD, Orrtwijn BD. et al. Clearance of von Willebrand factor. Thromb Haemost 2008; 99: 271-278.
4 Barberis L, Hirsch E. Targeting Phosphoinositide 3-kinase γ to fight inflammation and more. Thromb Haemost 2008; 99: 279-285.
5 Hirsch E, Katanaev VL, Garlanda C. et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 2000; 287: 1049-1053.
6 Kanse SM, Parahuleva M, Muhl L. et al. Factor VII activating protease (FSAP): Vascular functions and role in atheroschlerosis. Thromb Haemost 2008; 99: 286-289.
7 Samad F, Loskutoff DJ. The fat mouse: a powerful genetic model to study elevated plasminogen activator inhibitor 1 in obesity/NIDDM. Thromb Haemost 1997; 78: 652-655.
8 Christiaens V, Scroyen I, Lijnen HR. Role of proteolysis in development of murine adipose tissue. Thromb Haemost 2008; 99: 290-294.
9 Hughes M, Lip GYH. Stroke and thromboembolism in atrial fibrillation: A schematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295-304.